CN109463730A - A kind of composition containing cordycepin, liquid beverage, candy, solid beverage and tablet - Google Patents
A kind of composition containing cordycepin, liquid beverage, candy, solid beverage and tablet Download PDFInfo
- Publication number
- CN109463730A CN109463730A CN201811609606.XA CN201811609606A CN109463730A CN 109463730 A CN109463730 A CN 109463730A CN 201811609606 A CN201811609606 A CN 201811609606A CN 109463730 A CN109463730 A CN 109463730A
- Authority
- CN
- China
- Prior art keywords
- cordycepin
- composition
- theaflavin
- beverage
- candy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 title claims abstract description 45
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 title claims abstract description 45
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 235000013361 beverage Nutrition 0.000 title claims abstract description 32
- 239000007787 solid Substances 0.000 title claims abstract description 18
- 235000009508 confectionery Nutrition 0.000 title claims abstract description 17
- 239000007788 liquid Substances 0.000 title claims abstract description 17
- 235000014620 theaflavin Nutrition 0.000 claims abstract description 37
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 claims abstract description 36
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 claims abstract description 36
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 claims abstract description 36
- 229940026509 theaflavin Drugs 0.000 claims abstract description 36
- 239000000463 material Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 12
- 230000001093 anti-cancer Effects 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 10
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- -1 anti-inflammatory Substances 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 6
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 5
- 208000008589 Obesity Diseases 0.000 abstract description 5
- 241001248610 Ophiocordyceps sinensis Species 0.000 abstract description 5
- 230000003527 anti-angiogenesis Effects 0.000 abstract description 5
- 230000003178 anti-diabetic effect Effects 0.000 abstract description 5
- 230000002019 anti-mutation Effects 0.000 abstract description 5
- 230000000702 anti-platelet effect Effects 0.000 abstract description 5
- 239000003146 anticoagulant agent Substances 0.000 abstract description 5
- 239000003472 antidiabetic agent Substances 0.000 abstract description 5
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 5
- 235000020824 obesity Nutrition 0.000 abstract description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 5
- 230000000845 anti-microbial effect Effects 0.000 abstract description 4
- 230000001857 anti-mycotic effect Effects 0.000 abstract description 4
- 239000002543 antimycotic Substances 0.000 abstract description 4
- 239000003963 antioxidant agent Substances 0.000 abstract description 4
- 230000003078 antioxidant effect Effects 0.000 abstract description 4
- 235000006708 antioxidants Nutrition 0.000 abstract description 4
- 230000033228 biological regulation Effects 0.000 abstract description 4
- 230000001900 immune effect Effects 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 14
- 238000010171 animal model Methods 0.000 description 6
- 239000013065 commercial product Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- KMJPKUVSXFVQGZ-UHFFFAOYSA-N TF2B Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 KMJPKUVSXFVQGZ-UHFFFAOYSA-N 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GPLOTACQBREROW-UHFFFAOYSA-N Phlegmanol A-acetat Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC1=2)C=C(O)C(=O)C1=C(O)C(O)=CC=2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 GPLOTACQBREROW-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229920001202 Inulin Polymers 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- AATSUYYYTHJRJO-UHFFFAOYSA-N theaflavin 3-gallate Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC(=O)C(O)=C1C(O)=C2O)C=C1C=C2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 AATSUYYYTHJRJO-UHFFFAOYSA-N 0.000 description 2
- 235000007900 theaflavin-3-gallate Nutrition 0.000 description 2
- AATSUYYYTHJRJO-RZYARBFNSA-N theaflavin-3-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=C(O)C(O)=C2C(=O)C(O)=CC(=CC2=C1)[C@H]1OC2=CC(O)=CC(O)=C2C[C@H]1O)C(=O)C1=CC(O)=C(O)C(O)=C1 AATSUYYYTHJRJO-RZYARBFNSA-N 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002707 Digallic acid Polymers 0.000 description 1
- 101100424903 Homo sapiens GTF2B gene Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- BVMDSEFJGKQBKJ-UHFFFAOYSA-N Theaflavin 3'-gallate Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O BVMDSEFJGKQBKJ-UHFFFAOYSA-N 0.000 description 1
- 102100033662 Transcription initiation factor IIB Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000192 social effect Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 201000003570 spinocerebellar ataxia type 17 Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- IKLDTEFDTLKDRK-UHFFFAOYSA-N theaflavin 3'-gallate Natural products OC1Cc2c(O)cc(O)cc2OC1c3cc4C=C(C=C(O)C(=O)c4c(O)c3O)C5Oc6cc(O)cc(O)c6CC5OC(=O)c7cc(O)c(O)c(O)c7 IKLDTEFDTLKDRK-UHFFFAOYSA-N 0.000 description 1
- 235000002365 theaflavin-3'-gallate Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention provides a kind of composition containing cordycepin, liquid beverage, candy, solid beverage and tablets, belong to health care product, food technology field, the composition of the cordycepin includes theaflavin and cordycepin, and the mass ratio of the theaflavin and cordycepin is (0.0001~20): (0.0001~10).Cordyceps sinensis promotor composition provided by the invention has antimicrobial, anti-mutation, anti-rotation shifting, anti-angiogenesis, antimycotic, anti-diabetic, anti-inflammatory, anti-platelet aggregation, immunological regulation, hypoglycemic, anti-oxidant, anticancer, anti-cancer and resisting cardiovascular disease, adjusts the effect of blood lipid, losing weight and pre- preventing obesity.
Description
Technical field
The invention belongs to health care products, food technology field, and in particular to a kind of composition containing cordycepin, liquid drink
Material, candy, solid beverage and tablet.
Background technique
Cordycepin also known as 3'-Deoxyadenosine, cordycepin, cordycepin are a kind of with multiple biological function
Nucleosides antibiotics.Studies have shown that cordyceps sinensis is known as antimicrobial, antitumor, anti-mutation, anti-rotation shifting, anti-angiogenesis, resists very
Bacterium, anti-diabetic, anti-inflammatory, anti-platelet aggregation, immunological regulation, it is hypoglycemic the effects of.The biological function and pharmacology of cordycepin
Effect has caused the extensive concern of researchers at home and abroad.It recent studies have shown that cordycepin in anti-senile dementia disease, high urine
Acidaemia, antidepression, treatment or prevention osteoporosis, weight-reducing and control weight etc. all show potential prevention or therapeutic effect,
In current chronic disease and metabolic disease high-incidence today, provide it is a kind of take or absorb easily the product containing cordycepin have ten
Divide important social effect and economic value.
Theaflavins substance is that catechins aoxidize a kind of dimer to be formed in black tea, is soluble in ethyl acetate,
General name with the tall and erect phenolic ketone structural compounds of benzene a pair of horses going side by side.Its 2-6% for accounting for about black tea water extract dry weight, wherein content is highest main
For 4 kinds of kinds of theaflavin monomer: theaflavin (TF1), theaflavin-3-gallate (TF2A), theaflavin-3'-gallate
(TF2B) and theaflavin -3,3 '-digallic acid ester (TF3).Modern medicine, which shows theaflavin not only, has good antioxygen
Change, anti-inflammatory, antivirus action, also has effects that anticancer, anti-cancer and resisting cardiovascular disease.
Theaflavin is developed in the prior art and is developed for product, such as Shanghai Ke Bao biotech company in Global Success
Section's benefit soft capsule rich in the theaflavin factor.The one Nutrilite tea race benefit rouge capsule of blood fat-reducing product of Amway Company, U.S. exploitation,
It is exactly to reduce cholesterol using " active theaflavin " as the main composition of product and LDL is horizontal obvious.U.S. Nashai is raw
Object technology company also develops Theaflavin blood fat-reducing product.But do not have in the prior art theaflavin and cordycepin is organic
Combined product.
Summary of the invention
In view of this, containing in the composition the purpose of the present invention is to provide a kind of composition containing cordycepin
Cordycepin and theaflavin have antimicrobial, anti-mutation, anti-rotation shifting, anti-angiogenesis, antimycotic, anti-diabetic, anti-inflammatory, anti-
Platelet aggregation, immunological regulation, hypoglycemic, anti-oxidant, anticancer, anti-cancer and resisting cardiovascular disease adjust blood lipid, lose weight
The effect of with pre- preventing obesity.
In order to achieve the above-mentioned object of the invention, the present invention the following technical schemes are provided:
The present invention provides a kind of composition containing cordycepin, including theaflavin and cordycepin, the theaflavin and worm
The mass ratio of careless element is (0.0001~20): (0.0001~10).
Preferably, the mass ratio of the theaflavin and cordycepin is (0.1~18): (0.1~8).
The present invention also provides a kind of liquid beverages, composition, corrigent, preservative including above-mentioned technical proposal and
Water.
Preferably, in terms of the total amount of the liquid beverage, the mass percentage of the composition is 0.0001%~
5%.
The present invention also provides a kind of candies, composition and acceptable auxiliary material including above-mentioned technical proposal.
Preferably, in terms of the total amount of the candy, the mass percentage of the composition is 0.001%~5%.
The present invention also provides a kind of solid beverages, composition and acceptable auxiliary material including above-mentioned technical proposal.
Preferably, in terms of the total amount of the solid beverage, the mass percentage of the composition is 0.1%~20%.
The present invention also provides a kind of tablets, composition and acceptable auxiliary material including above-mentioned technical proposal.
Preferably, in terms of the total amount of the tablet, the mass percentage of the composition is 0.1%~20%.
The present invention provides a kind of composition containing cordycepin, contain cordycepin and theaflavin in the composition,
Under the action of cordycepin and theaflavin, have antimicrobial, anti-mutation, anti-rotation shifting, anti-angiogenesis, antimycotic, anti-diabetic,
The effect of anti-inflammatory, anti-platelet aggregation, immunological regulation, hypoglycemic, anti-oxidant, anticancer, anti-cancer and resisting cardiovascular disease.
The embodiment of the present invention is as the result is shown: the composition provided by the invention containing cordycepin, in cordycepin and theaflavin
Under the action of, have the function of adjusting blood lipid, losing weight and pre- preventing obesity.
Specific embodiment
The present invention provides a kind of composition containing cordycepin, including theaflavin and cordycepin, the theaflavin and worm
The mass ratio of careless element is (0.0001~20): (0.0001~10).
The present invention is not particularly limited the source of the theaflavin and cordycepin, using conventional commercial product.
In the present invention, the mass ratio of the theaflavin and cordycepin is (0.0001~20): (0.0001~10), preferably
For (0.001~20): (0.001~10), most preferably (0.01~20): (0.01~10).In the present invention, the theaflavin
Have effects that anti-oxidant, anti-inflammatory, antiviral, anticancer, anti-cancer and resisting cardiovascular disease；The cordycepin, which has, resists micro- life
Object, antitumor, anti-mutation, anti-rotation shifting, anti-angiogenesis, antimycotic, anti-diabetic, anti-inflammatory, anti-platelet aggregation, immune tune
The effect of section, hypoglycemic, pre- preventing obesity and weight-reducing.
The present invention also provides a kind of liquid beverages, including composition, corrigent described in above-mentioned technical proposal, preservative
And water.The present invention is not particularly limited the preparation method of the liquid beverage, using the conventional preparation side for preparing liquid beverage
Method.
The present invention is not particularly limited the type of the corrigent, preservative and source, using conventional commercial product
?.
The present invention preferably in terms of the total amount of liquid beverage, the mass percentage of the composition is preferably 0.0001%~
5%, more preferably 0.001%~5%, most preferably 0.01%~5%.
The present invention also provides a kind of candies, composition and acceptable auxiliary material including above-mentioned technical proposal.The present invention
The preparation method of the candy is not particularly limited, using the conventional preparation method for preparing candy.
The present invention is not particularly limited the type of the acceptable auxiliary material and source, is using conventional commercial product
It can.
The present invention preferably in terms of the total amount of the candy, the mass percentage of the composition is preferably 0.001%~
5%, more preferably 0.01%~5%, most preferably 0.1%~5%.
The present invention also provides a kind of solid beverages, composition and acceptable auxiliary material including above-mentioned technical proposal.This
Invention is not particularly limited the preparation method of the solid beverage, using the conventional preparation method for preparing solid beverage.
The present invention is not particularly limited the type of the acceptable auxiliary material and source, is using conventional commercial product
It can.
For the present invention preferably in terms of the total amount of the solid beverage, the mass percentage of the composition is preferably 0.1%
~20%, more preferably 0.2%~19%, most preferably 0.3%~18%.
The present invention also provides a kind of tablets, composition and acceptable auxiliary material including above-mentioned technical proposal.The present invention
The preparation method of the tablet is not particularly limited, using the conventional preparation method for preparing tablet.
The present invention is not particularly limited the type of the acceptable auxiliary material and source, is using conventional commercial product
It can.
The present invention preferably in terms of the total amount of the tablet, the mass percentage of the composition is preferably 0.1%~
20%, more preferably 0.2%~19%, most preferably 0.3%~18%.
Below in conjunction with the embodiment in the present invention, technical solution provided by the invention is clearly and completely retouched
It states.Obviously, described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.Based on the present invention
In embodiment, every other implementation obtained by those of ordinary skill in the art without making creative efforts
Example, shall fall within the protection scope of the present invention.
Embodiment 1
0.5g cordycepin, 0.5g theaflavin, 10g oligofructose and 1000ml purified water are mixed, using conventional preparation
1000ml liquid beverage is made in the method for liquid beverage, wherein the content difference in every milliliters of liquid beverage containing effective component
For cordycepin 0.005g, theaflavin 0.005g.
Embodiment 2
5g cordycepin, 5g theaflavin, 300g xylitol, 300g oligofructose and 390g inulin are mixed, using conventional system
1000 pressed candies are made in the method for standby pressed candy.Content in every candy containing effective component is respectively cordycepin
0.005g, theaflavin 0.005g.
Embodiment 3
It will be mixed containing 1g cordycepin, 1g theaflavin, 300g oligofructose and 698g inulin, and prepare solid drink using conventional
1000g solid beverage is made in the method for material.The content of every bag of solid beverage is 10g, contains effective component in every bag of solid beverage
Content be respectively cordycepin 0.01g, theaflavin 0.01g.
Embodiment 4
The product that embodiment 1 is prepared feeds mouse, the specific steps are as follows:
SD rat 18, male, cleaning grade, 180~200g of weight, purchased from Academy of Military Medicine, PLA
Experimental Animal Center, experimental animal use credit number: SCXK2015-0001.Testing the feed used is 60% feeding high in fat
Material.18 experimental animals are randomly divided into 3 groups, every group 6, Normal group gives basal feed, and model group gives feeding high in fat
Material, product group distinguish 1 liquid preparation of stomach-filling embodiment (contained cordycepin, theaflavin content except feeding high lipid food external demand daily
It is scaled 25mg/Kg respectively).After raising 30d, after fasting 12h, weighs after last dose 1h, the results are shown in Table 1.
The changes of weight when product of 1 embodiment 1 of table preparation is fed mouse 30 days
Remarks: compared with the control group, * is indicated significant difference (P < 0.05) product group；* indicates extremely significant (the P < of difference
0.01)；Product group is compared with model group, *, indicates significant difference (P < 0.05)；* indicates that difference is extremely significant (P < 0.01)
From the result of above-mentioned table 1: having using the product provided by the invention containing the preparation of cordyceps sinensis promotor composition aobvious
Write the effect lost weight.
Embodiment 5
The product that embodiment 2 is prepared feeds mouse, detects regulating plasma lipid and changes of weight, specific steps
It is as follows:
SD rat 30, male, cleaning grade, 180~200g of weight, purchased from Academy of Military Medicine, PLA
Experimental Animal Center, experimental animal use credit number: SCXK2015-0001.Testing the feed used is 60% feeding high in fat
Material.It will only weigh after rat adaptable fed 1 week for every group 10 after modeling success, 30 experimental animals be randomly divided into 3 groups, every group
10, Normal group gives basal feed, and model group gives high lipid food, and product group is except the feeding every natural gift of high lipid food external demand
The pressed candy aqueous solution of other stomach-filling embodiment 2 (contained cordycepin, theaflavin content are scaled 25mg/Kg respectively).Raise 35d
Afterwards, it after fasting 12h, weighs after last dose 1h, docking takes blood, blood room temperature 2h, after 3000r/min is centrifuged 30min
Serum is collected, detects TC, TG, LDL, HDL4 blood lipids index using lipids detection kit, and after rat anesthesia is put to death, take
Intraperitoneal white adipose weighing, and calculate fat coefficient.Fat coefficient (%)=(intraperitoneal white adipose weight (g)/weight
(g)) × 100%.It the results are shown in Table 2.
2 embodiment 2 of table prepares product to the regulating plasma lipid and changes of weight result of mouse
| Detection project | Control group | Model group | Product group |
| TC mean value | 0.98±0.21 | 4.75±0.32** | 2.48±0.51** |
| TG mean value | 0.49±0.12 | 1.27±0.21** | 0.74±0.16** |
| LDL mean value | 0.63±0.21 | 1.51±0.35** | 0.79±0.31** |
| HDL mean value | 0.85±0.18 | 0.23±0.04** | 0.54±0.11** |
| Weight mean value | 432±17.1 | 529±18.9** | 455±14.8* |
| Fat coefficient | 18.50±1.20 | 28.9±0.98** | 20.1±1.16* |
Remarks: product group and control group, * are indicated significant difference (P < 0.05)；* indicates extremely significant (the P < of difference
0.01)；Product group is compared with model group, *, indicates significant difference (P < 0.05)；* indicates extremely significant (the P < of difference
0.01)
From the result of above-mentioned table 2: having using the product provided by the invention containing the preparation of cordyceps sinensis promotor composition and adjust
It saves blood lipid and controls the effect of weight.
Embodiment 6
Product prepared by embodiment 3 feeds mouse, detection mouse weight variation, the specific steps are as follows:
SD rat 18, male, cleaning grade, 180~200g of weight, purchased from Academy of Military Medicine, PLA
Experimental Animal Center, experimental animal use credit number: SCXK2015-0001.Testing the feed used is 60% feeding high in fat
Material.18 experimental animals are randomly divided into 3 groups, every group 6, Normal group gives basal feed, and model group gives feeding high in fat
Material, (contained cordycepin, tea are yellow except feeding high lipid food external demand distinguishes 3 solid beverage aqueous solution of stomach-filling embodiment daily for product group
Cellulose content is scaled 25mg/Kg respectively).After raising 30d, after fasting 12h, weigh after last dose 1h.It the results are shown in Table 3.
3 embodiment 3 of table prepares changes of weight result when product is fed mouse 30 days
Remarks: compared with the control group, * is indicated significant difference (P < 0.05) product group；* indicates extremely significant (the P < of difference
0.01)；Product group is compared with model group, *, indicates significant difference (P < 0.05)；* indicates that difference is extremely significant (P < 0.01)
From the result of above-mentioned table 3: having using the product provided by the invention containing the preparation of cordyceps sinensis promotor composition aobvious
Write the effect lost weight.
As can be seen from the above embodiments, the composition provided by the invention containing cordycepin, in cordycepin and theaflavin
Under effect, have the function of adjusting blood lipid, losing weight and pre- preventing obesity.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (10)
1. the mass ratio of a kind of composition containing cordycepin, including theaflavin and cordycepin, the theaflavin and cordycepin is
(0.0001~20): (0.0001~10).
2. composition according to claim 1, which is characterized in that the mass ratio of the theaflavin and cordycepin be (0.1~
18): (0.1~8).
3. a kind of liquid beverage, including composition of any of claims 1 or 2, corrigent, preservative and water.
4. liquid beverage according to claim 3, which is characterized in that in terms of the total amount of the liquid beverage, the combination
The mass percentage of object is 0.0001%~5%.
5. a kind of candy, including composition of any of claims 1 or 2 and acceptable auxiliary material.
6. candy according to claim 5, which is characterized in that in terms of the total amount of the candy, the quality of the composition
Percentage composition is 0.001%~5%.
7. a kind of solid beverage, including composition of any of claims 1 or 2 and acceptable auxiliary material.
8. solid beverage according to claim 7, which is characterized in that in terms of the total amount of the solid beverage, the combination
The mass percentage of object is 0.1%~20%.
9. a kind of tablet, including composition of any of claims 1 or 2 and acceptable auxiliary material.
10. tablet according to claim 9, which is characterized in that in terms of the total amount of the tablet, the quality of the composition
Percentage composition is 0.1%~20%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811609606.XA CN109463730A (en) | 2018-12-27 | 2018-12-27 | A kind of composition containing cordycepin, liquid beverage, candy, solid beverage and tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811609606.XA CN109463730A (en) | 2018-12-27 | 2018-12-27 | A kind of composition containing cordycepin, liquid beverage, candy, solid beverage and tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109463730A true CN109463730A (en) | 2019-03-15 |
Family
ID=65678052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811609606.XA Pending CN109463730A (en) | 2018-12-27 | 2018-12-27 | A kind of composition containing cordycepin, liquid beverage, candy, solid beverage and tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109463730A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111480756A (en) * | 2020-05-09 | 2020-08-04 | 江苏德和生物科技有限公司 | Theaflavin composition for relieving asthenopia and preparation method thereof |
| CN113908150A (en) * | 2021-11-02 | 2022-01-11 | 华中科技大学同济医学院附属协和医院 | Application of theaflavin-3, 3' -digallate or its derivative in smooth muscle phenotype transformation inhibitor |
| CN115501245A (en) * | 2022-10-12 | 2022-12-23 | 刘笛 | Components for resisting birth canal cell damage and promoting elastin synthesis and application |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103230015A (en) * | 2013-05-20 | 2013-08-07 | 李铁清 | Extract compound for delaying senility, improving immunity and preventing and resisting cancer |
| CN105532998A (en) * | 2015-12-24 | 2016-05-04 | 邓维国 | Health-care tea containing cordyceps militaris and preparation method thereof |
| CN107624943A (en) * | 2017-11-08 | 2018-01-26 | 深圳瑞德源健康科技有限公司 | A kind of jerusalem artichoke pressed candy and preparation method thereof |
| CN107737136A (en) * | 2017-08-23 | 2018-02-27 | 深圳清华大学研究院 | A kind of purposes of pharmaceutical composition in preventing and/or treating hyperlipidemia and be hypoglycemic |
| CN108272814A (en) * | 2018-04-27 | 2018-07-13 | 深圳松乐生物科技有限公司 | A kind of composition and its application containing cordycepin |
| KR20180082784A (en) * | 2017-01-11 | 2018-07-19 | (주)루스바이오 | The composition of Cordyceps militaris comprising codycepin for inhibting dissolution codycepin, and the functional foods composition |
-
2018
- 2018-12-27 CN CN201811609606.XA patent/CN109463730A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103230015A (en) * | 2013-05-20 | 2013-08-07 | 李铁清 | Extract compound for delaying senility, improving immunity and preventing and resisting cancer |
| CN105532998A (en) * | 2015-12-24 | 2016-05-04 | 邓维国 | Health-care tea containing cordyceps militaris and preparation method thereof |
| KR20180082784A (en) * | 2017-01-11 | 2018-07-19 | (주)루스바이오 | The composition of Cordyceps militaris comprising codycepin for inhibting dissolution codycepin, and the functional foods composition |
| CN107737136A (en) * | 2017-08-23 | 2018-02-27 | 深圳清华大学研究院 | A kind of purposes of pharmaceutical composition in preventing and/or treating hyperlipidemia and be hypoglycemic |
| CN107624943A (en) * | 2017-11-08 | 2018-01-26 | 深圳瑞德源健康科技有限公司 | A kind of jerusalem artichoke pressed candy and preparation method thereof |
| CN108272814A (en) * | 2018-04-27 | 2018-07-13 | 深圳松乐生物科技有限公司 | A kind of composition and its application containing cordycepin |
Non-Patent Citations (4)
| Title |
|---|
| 上海国宝企业发展中心专题报道组: "上海国宝企业发展中心:以研发引领虫草素产业化", 《中国科技产业》 * |
| 孙世利等: "茶多酚与茶黄素对前脂肪细胞3T3-L1增殖与分化的影响", 《广东农业科学》 * |
| 李燕等: "虫草素预防肥胖及通过ADORA_1介导GH3细胞中泌乳素分泌研究", 《中国畜牧兽医》 * |
| 蒋慧颖等: "茶黄素、茶红素与茶褐素对高脂饮食大鼠肠道菌群的影响", 《食品工业科技》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111480756A (en) * | 2020-05-09 | 2020-08-04 | 江苏德和生物科技有限公司 | Theaflavin composition for relieving asthenopia and preparation method thereof |
| CN113908150A (en) * | 2021-11-02 | 2022-01-11 | 华中科技大学同济医学院附属协和医院 | Application of theaflavin-3, 3' -digallate or its derivative in smooth muscle phenotype transformation inhibitor |
| CN115501245A (en) * | 2022-10-12 | 2022-12-23 | 刘笛 | Components for resisting birth canal cell damage and promoting elastin synthesis and application |
| CN115501245B (en) * | 2022-10-12 | 2023-10-31 | 西安萱御制药集团有限公司 | Component for resisting cell damage of birth canal and promoting elastin synthesis and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8445035B2 (en) | Dietary supplements containing extracts of aronia and method of using same to promote weight loss | |
| CN109463730A (en) | A kind of composition containing cordycepin, liquid beverage, candy, solid beverage and tablet | |
| WO1999042096A1 (en) | Composition comprising theanine | |
| CN105169203B (en) | A kind of Fructus Amomi extract and application thereof | |
| CN102511814B (en) | Composition with lipase inhibiting effect and application of same | |
| CN105031042A (en) | Medicinal composition having weight-loss function and application of medicinal composition | |
| CN111227153A (en) | Dietary food for whitening, detoxifying and slimming | |
| WO2006112366A1 (en) | Lipopexia inhibitor and food or beverage | |
| CN105941779A (en) | Combined drink of maca, milk and coffee and preparation method of combined drink | |
| CN108095118A (en) | A kind of slimming health food | |
| JP2005278478A (en) | Rebound preventing beverage and fat absorption restraining agent each containing post-heating fermented tea | |
| CN102669370A (en) | Lotus leaf balsam pear tea and preparation method thereof | |
| KR100851586B1 (en) | Composition comprising Lactobacillus for inhibiting obesity | |
| CN104223304B (en) | A kind of spirit can the product that menopause symptom be improved and preparation method thereof of releiving | |
| CN102366094A (en) | Fat-reducing and hypolipemic health food | |
| CN104824779A (en) | Theabrownin health-caring solid beverage | |
| CN106822647A (en) | A kind of hypoglycemic compound preparation of lipid-loweringing and preparation method thereof | |
| JP2007070263A (en) | Composition for preventing diabetes mellitus | |
| US20080207717A1 (en) | Composition to provide maintenance and nutritional support in glycemic control deficits | |
| KR101336068B1 (en) | Anti-diabetes composition comprising oriental herbal extracts and fractions | |
| CN105381313A (en) | Vitamin D composition and application thereof | |
| KR102501548B1 (en) | A composition for improving, preventing and treating of fatty liver diseases comprising leek extract | |
| US11896608B1 (en) | Alcohol metabolism acceleration composition | |
| KR102441481B1 (en) | Method for manufacturing black barley coffee using a black barley extract, and the black barley coffee menufactued by the method | |
| LU501691B1 (en) | Composition with weight-losing and lipid-lowering activity and product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 518057 research building C411, Research Institute of Tsinghua University, Shenzhen, Nanshan District, Guangdong Applicant after: Shenzhen songzhile Biotechnology Co., Ltd Address before: 518000 research building C411, Research Institute of Tsinghua University, Shenzhen, Nanshan District, Guangdong Applicant before: SHENZHEN SONGLE BIOTECHNOLOGY Co.,Ltd. |